Status:
COMPLETED
Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis
Lead Sponsor:
Mersin University
Conditions:
Endometriosis
Eligibility:
FEMALE
3-12 years
Phase:
EARLY_PHASE1
Brief Summary
Current endometriosis therapy is based on interrupting the menstrual cycle and suppression of estrogen synthesis in order to induce atrophy of endometrial tissue. Progestins, oral contraceptives, andr...
Detailed Description
Endometriosis is a relatively common benign disorder that causes significant health problems with yet an unknown etiology. The disease which is defined as the presence of the endometrial gland and str...
Eligibility Criteria
Inclusion
- non-pregnant, sexually mature albino rats weighing between 180-240 g
Exclusion
- pregnant, non-healthy, sexually immature, weighing \<180 g
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04844996
Start Date
September 1 2019
End Date
January 31 2021
Last Update
April 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mersin University
Mersin, Turkey (Türkiye), 33343